• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Apria Announces Expiration of Hart-Scott-Rodino Waiting Period

    2/24/22 4:05:00 PM ET
    $APR
    Medical/Dental Instruments
    Health Care
    Get the next $APR alert in real time by email

    INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company's outstanding common stock and other customary closing conditions.

    About Apria

    Apria is a leading provider of integrated home healthcare equipment and related services in the United States, providing home respiratory therapy, obstructive sleep apnea treatment and negative pressure wound therapy. Its approximately 280 locations throughout the continental United States and Hawaii serve nearly 2 million patients each year. All of Apria's locations are accredited by The Joint Commission.

    Investor Contact

    Kevin Ellich

    Westwicke

    [email protected]

    Media Contact

    Kyle Evans

    Westwicke

    [email protected]

    Forward-Looking Statements

    This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, statements regarding Apria, Inc.'s ("Apria") expectations regarding the proposed acquisition of Apria by Owens & Minor Inc. (the "proposed merger") and the future performance and financial results of Apria's business and other non-historical statements. Some of these statements can be identified by terms and phrases such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. Apria cautions readers of this communication that such "forward looking statements", wherever they occur in this communication or in other statements attributable to Apria, are necessarily estimates reflecting the judgment of Apria's senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward looking statements."

    Factors that could cause Apria's actual results to differ materially from those expressed or implied in such forward-looking statements include, but are not limited to: the occurrence of any event, change or other circumstances that could give rise to the termination of the merger agreement relating to the proposed merger; the inability to complete the proposed merger due to the failure to obtain approval of Apria's stockholders for the proposed merger or the failure to satisfy other conditions to completion of the proposed merger, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed merger; risks related to disruption of management's attention from Apria's ongoing business operations due to the proposed merger; the effect of the announcement of the proposed merger on Apria's relationships with its customers, suppliers and other third parties, as well as its operating results and business generally; the risk that the proposed merger will not be consummated in a timely manner; exceeding the expected costs of the merger; risks related to the COVID-19 public health emergency, product and related recalls; the profitability of Apria's capitation arrangements; renegotiation or termination of Apria's contracts; reimbursements by payors; our reliance on relatively few vendors; competition in the home healthcare industry; the inherent risk of liability in the provision of healthcare services; and reductions in Medicare and Medicaid and commercial payor reimbursement rates.

    Additional factors that could cause Apria's actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the "Risk Factors" sections of Apria's Annual Report on Form 10-K for the period ended December 31, 2020 and Quarterly Reports on Form 10-Q for the periods ended June 30, 2021 and September 30, 2021, as such factors may be further updated from time to time in Apria's other filings with the Securities and Exchange Commission ("SEC"). These reports are or will be accessible on the SEC's website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this press release and in Apria's filings with the SEC. Apria undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

    Additional Information and Where to Find It

    In connection with the proposed merger, Apria filed with the SEC on February 22, 2022 and furnish to Apria's stockholders a definitive proxy statement. Stockholders are urged to read such proxy statement and any other documents to be filed with the SEC in connection with the proposed merger or incorporated by reference in the proxy statement because they will contain important information about the proposed merger. This filing does not constitute a solicitation of any vote or approval.

    Investors are able to obtain free of charge the definitive proxy statement and other documents filed with the SEC at the SEC's website at http://www.sec.gov. In addition, the definitive proxy statement and Apria's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports filed or furnished pursuant to section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, are available free of charge through Apria's website at www.apria.com. as soon as reasonably practicable after they are electronically filed with, or furnished to, the SEC.

    The directors, executive officers and certain other members of management and employees of Apria may be deemed "participants" in the solicitation of proxies from stockholders of Apria in favor of the proposed merger. Information regarding the persons who may, under the rules of the SEC, be considered participants in the solicitation of the stockholders of Apria in connection with the proposed merger are set forth in the definitive proxy statement and the other relevant documents filed with the SEC. You can find information about Apria's executive officers and directors in its Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and Current Report on Form 8-K filed with the SEC on May 6, 2021.



    Primary Logo

    Get the next $APR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APR

    DatePrice TargetRatingAnalyst
    1/11/2022$37.50Buy → Neutral
    UBS
    1/10/2022$39.00Buy
    Citigroup
    11/19/2021$39.00Buy
    Citigroup
    11/8/2021$43.00Buy
    Citigroup
    7/19/2021$32.00 → $29.00Buy → Neutral
    Goldman Sachs
    6/30/2021$33.00Buy
    Citigroup
    More analyst ratings

    $APR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Apria Announces Financial Results for Fourth Quarter and Full Year 2021

    INDIANAPOLIS, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of integrated home healthcare equipment and related services in the United States, announced today financial results for the fourth quarter and full year ended December 31, 2021. As previously announced, the Company will not be hosting a conference call to discuss its financial results. "We reported solid fourth quarter financial results and 2021 was a good year for Apria. Our team did an excellent job operating and executing at a high level while navigating the challenges from the COVID-19 pandemic, as well as a major product recall and supply chain constraints. Fourth

    2/28/22 6:30:00 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    Apria Announces Expiration of Hart-Scott-Rodino Waiting Period

    INDIANAPOLIS, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today that the waiting period has expired under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, in connection with its previously announced transaction with Owens & Minor, Inc. The closing of the transaction remains subject to approval by holders of a majority of the Company's outstanding common stock and other customary closing conditions. About Apria Apria is a leading provider of integrated home healthcare equipment and related services in the United States,

    2/24/22 4:05:00 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.

    Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil

    1/10/22 6:00:00 AM ET
    $APR
    $OMI
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    $APR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Apria downgraded by UBS with a new price target

    UBS downgraded Apria from Buy to Neutral and set a new price target of $37.50

    1/11/22 6:43:54 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Apria with a new price target

    Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00

    1/10/22 7:15:48 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    Citigroup resumed coverage on Apria with a new price target

    Citigroup resumed coverage of Apria with a rating of Buy and set a new price target of $39.00

    11/19/21 7:12:27 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    $APR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4: Walker Robert P. returned $192,450 worth of shares to the company (5,132 units at $37.50), closing all direct ownership in the company (tax liability)

    4 - Apria, Inc. (0001735803) (Issuer)

    3/29/22 4:31:49 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    SEC Form 4: Apria Holdings Llc sold $532,031,812 worth of shares (14,187,515 units at $37.50)

    4 - Apria, Inc. (0001735803) (Issuer)

    3/29/22 4:31:15 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Snyder Lynn Shapiro to satisfy withholding obligation

    4 - Apria, Inc. (0001735803) (Issuer)

    3/29/22 4:31:20 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    $APR
    SEC Filings

    View All

    SEC Form 15-12B filed by Apria Inc.

    15-12B - Apria, Inc. (0001735803) (Filer)

    4/8/22 10:10:58 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    SEC Form 25-NSE filed by Apria Inc.

    25-NSE - Apria, Inc. (0001735803) (Subject)

    3/29/22 8:55:14 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Apria Inc.

    S-8 POS - Apria, Inc. (0001735803) (Filer)

    3/29/22 8:35:01 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    $APR
    Leadership Updates

    Live Leadership Updates

    View All

    Apria Appoints Christopher G. Lee as Chief Accounting Officer

    INDIANAPOLIS, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR), a leading provider of home medical equipment, supplies and related services in the United States, announced today the appointment of Christopher G. Lee as Chief Accounting Officer, a newly created position. Mr. Lee will report to Debra Morris, Apria's Chief Financial Officer. Mr. Lee has 18 years of accounting and financial leadership experience. He joined Apria in February 2009 and has risen internally to his most recent role as Senior Vice President, Accounting and Finance. Prior to joining Apria, Mr. Lee was with Deloitte & Touche. Mr. Lee is a graduate of the University of California a

    10/4/21 8:00:00 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    $APR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by Apria Inc. (Amendment)

    SC 13G/A - Apria, Inc. (0001735803) (Subject)

    4/8/22 4:04:00 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Apria Inc.

    SC 13G - Apria, Inc. (0001735803) (Subject)

    3/10/22 5:01:54 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Apria Inc.

    SC 13G - Apria, Inc. (0001735803) (Subject)

    2/14/22 4:06:09 PM ET
    $APR
    Medical/Dental Instruments
    Health Care

    $APR
    Financials

    Live finance-specific insights

    View All

    Owens & Minor, Inc. Signs Definitive Agreement to Acquire Apria, Inc.

    Highly Complementary Transaction Expands Patient Direct Offering Year-One Accretion Across Key Financial Metrics and Free Cash Flow Enhancement Creates a Leading Platform for Future Growth Owens & Minor, Inc. ("Owens & Minor") (NYSE:OMI) and Apria, Inc. ("Apria") (NASDAQ:APR) today announced that the companies have entered into a definitive agreement pursuant to which Owens & Minor will acquire Apria for $37.50 in cash per share of common stock, representing an equity value of approximately $1.45 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220110005291/en/ "I'm very excited about the acquisition of Apria, which wil

    1/10/22 6:00:00 AM ET
    $APR
    $OMI
    Medical/Dental Instruments
    Health Care
    Medical Specialities

    Apria to Announce Third Quarter 2021 Financial Results

    INDIANAPOLIS, Oct. 21, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal third quarter 2021 financial results on Thursday, November 4, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID 4161279; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listeni

    10/21/21 8:00:00 AM ET
    $APR
    Medical/Dental Instruments
    Health Care

    Apria to Announce Second Quarter 2021 Financial Results

    INDIANAPOLIS, July 22, 2021 (GLOBE NEWSWIRE) -- Apria, Inc. (the "Company" or "Apria") (NASDAQ:APR) announced today that it will release fiscal second quarter 2021 financial results on Thursday, August 5, 2021 after the market closes. In conjunction, the company will host a conference call to review results at 5:00 p.m. (ET) on the same day. Conference Call Details The conference call can be accessed by dialing (833) 362-0207 for U.S. participants, or (914) 987-7676 for international participants, referencing conference ID # 5380517; or via a live audio webcast that will be available online at https://ir.apria.com/. A replay of the call will be available via webcast for on-demand listen

    7/22/21 4:05:00 PM ET
    $APR
    Medical/Dental Instruments
    Health Care